Figure 4. Tissue-on-a-chip models.

potentially allow for high-throughput screening of pharmaceuticals in vitro on human cell-based substrates in a relatively cost effective manner when compared to typical testing methods that involve extensive testing on explanted animal heart tissue slices and pre-clinical studies. These platforms can be tailored to specific diseases using cell lines from the affected patients, and exhibit the tissue response properties of the native cardiac tissue.